Stocktoria
GRI Bio, Inc. GRI
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-02-10
GRI Bio, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating margin | — | — | — | — | — | -4788.0% |
| Net margin | — | — | — | — | — | -4822.0% |
| FCF margin | — | — | — | — | — | -3708.0% |
| Return on assets | -138.0% | -143.0% | -441.0% | -839.9% | -111.6% | -504.9% |
| Return on equity | -199.0% | -203.5% | -5033.6% | 198.0% | 191.9% | 331.6% |
| Current ratio | 3.25 | 3.43 | 1.09 | 0.16 | 3.32 | 0.30 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.